Guiding the optimal translation of new cancer treatments from canine to human cancer patients

Chand Khanna; Cheryl London; David Vail; Christina Mazcko; Steven Hirschfeld

doi:10.1158/1078-0432.CCR-09-0719

Guiding the optimal translation of new cancer treatments from canine to human cancer patients

Chand Khanna^*
, Cheryl London
, David Vail
, Christina Mazcko
, Steven Hirschfeld

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Review article › peer-review

88 Scopus citations

Abstract

On June 20, 2008, a meeting entitled "Translation of new cancer treatments from canine to human cancer patients," sponsored by the National Cancer Institute in Bethesda, Maryland, was convened to discuss the potential value, opportunity, risks, and rewards of an integrated and comparative drug development path for new cancer therapeutics that includes naturally occurring cancers in pet animals. A summary of this meeting and subsequent discussion are provided here to afford clarity on the conduct of these studies so as to optimize the opportunities provided by this novel drug development and modeling strategy.

Original language	English
Pages (from-to)	5671-5677
Number of pages	7
Journal	Clinical Cancer Research
Volume	15
Issue number	18
DOIs	https://doi.org/10.1158/1078-0432.CCR-09-0719
State	Published - 15 Sep 2009

Access to Document

10.1158/1078-0432.CCR-09-0719

Cite this

@article{b3104a98d6d946ae927db32e8616efc8,

title = "Guiding the optimal translation of new cancer treatments from canine to human cancer patients",

abstract = "On June 20, 2008, a meeting entitled {"}Translation of new cancer treatments from canine to human cancer patients,{"} sponsored by the National Cancer Institute in Bethesda, Maryland, was convened to discuss the potential value, opportunity, risks, and rewards of an integrated and comparative drug development path for new cancer therapeutics that includes naturally occurring cancers in pet animals. A summary of this meeting and subsequent discussion are provided here to afford clarity on the conduct of these studies so as to optimize the opportunities provided by this novel drug development and modeling strategy.",

author = "Chand Khanna and Cheryl London and David Vail and Christina Mazcko and Steven Hirschfeld",

year = "2009",

month = sep,

day = "15",

doi = "10.1158/1078-0432.CCR-09-0719",

language = "English",

volume = "15",

pages = "5671--5677",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "18",

}

TY - JOUR

T1 - Guiding the optimal translation of new cancer treatments from canine to human cancer patients

AU - Khanna, Chand

AU - London, Cheryl

AU - Vail, David

AU - Mazcko, Christina

AU - Hirschfeld, Steven

PY - 2009/9/15

Y1 - 2009/9/15

N2 - On June 20, 2008, a meeting entitled "Translation of new cancer treatments from canine to human cancer patients," sponsored by the National Cancer Institute in Bethesda, Maryland, was convened to discuss the potential value, opportunity, risks, and rewards of an integrated and comparative drug development path for new cancer therapeutics that includes naturally occurring cancers in pet animals. A summary of this meeting and subsequent discussion are provided here to afford clarity on the conduct of these studies so as to optimize the opportunities provided by this novel drug development and modeling strategy.

AB - On June 20, 2008, a meeting entitled "Translation of new cancer treatments from canine to human cancer patients," sponsored by the National Cancer Institute in Bethesda, Maryland, was convened to discuss the potential value, opportunity, risks, and rewards of an integrated and comparative drug development path for new cancer therapeutics that includes naturally occurring cancers in pet animals. A summary of this meeting and subsequent discussion are provided here to afford clarity on the conduct of these studies so as to optimize the opportunities provided by this novel drug development and modeling strategy.

UR - https://www.scopus.com/pages/publications/70349437467

U2 - 10.1158/1078-0432.CCR-09-0719

DO - 10.1158/1078-0432.CCR-09-0719

M3 - Review article

C2 - 19737961

AN - SCOPUS:70349437467

SN - 1078-0432

VL - 15

SP - 5671

EP - 5677

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 18

ER -

Guiding the optimal translation of new cancer treatments from canine to human cancer patients

Abstract

Access to Document

Fingerprint

Cite this